ADVM
Adverum Biotechnologies Inc

5,109
Mkt Cap
$88.76M
Volume
157,916.00
52W High
$8.18
52W Low
$1.78
PE Ratio
-0.54
ADVM Fundamentals
Price
$4.23
Prev Close
$4.23
Open
$4.24
50D MA
$3.92
Beta
1.04
Avg. Volume
636,653.62
EPS (Annual)
-$6.62
P/B
-4.39
Rev/Employee
$6,451.61
Loading...
Loading...
News
all
press releases
HALPER SADEH LLC ENCOURAGES ADVM, PLYM, RNA SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS
HALPER SADEH LLC ENCOURAGES ADVM, PLYM, RNA SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS HALPER SADEH LLC ENCOURAGES ADVM, PLYM, RNA SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR...
PR Newswire·3d ago
News Placeholder
More News
News Placeholder
Buy, Sell or Hold Lilly Stock? Key Tips Ahead of Q3 Earnings
Eli Lilly's Q3 results hinge on strong demand for Mounjaro and Zepbound as investors weigh growth drivers against the pressure of pricing and competition.
Zacks·3d ago
News Placeholder
ADVM Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Adverum Biotechnologies, Inc. Is Fair to Shareholders
Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Adverum Biotechnologies, Inc. (NASDAQ: ADVM) to Eli Lilly and Company is fair to Adverum shareholders. Under the...
Business Wire·3d ago
News Placeholder
Adverum Biotechnologies Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Adverum Biotechnologies, Inc. - ADVM
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (KSF) are investigating the proposed sale of Adverum Biotechnologies, Inc. (NasdaqCM: ADVM...
Business Wire·5d ago
News Placeholder
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Adverum Biotechnologies, Inc. (NASDAQ: ADVM)
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Adverum Biotechnologies, Inc. (NASDAQ: ADVM) $HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of...
PR Newswire·6d ago
News Placeholder
Shareholder Alert: The Ademi Firm investigates whether Adverum Biotechnologies, Inc. is obtaining a Fair Price for its Public Shareholders
Shareholder Alert: The Ademi Firm investigates whether Adverum Biotechnologies, Inc. is obtaining a Fair Price for its Public Shareholders Shareholder Alert: The Ademi Firm investigates whether...
PR Newswire·6d ago
News Placeholder
Eli Lilly To Acquire Adverum Biotechnologies
Stocktwits·6d ago
News Placeholder
Lilly to Acquire Adverum Biotechnologies
Lilly to Acquire Adverum Biotechnologies Lilly to Acquire Adverum Biotechnologies PR Newswire INDIANAPOLIS and REDWOOD CITY, Calif., Oct. 24, 2025 Adverum's lead program, Ixo-vec, is a Phase 3 gene...
PR Newswire·6d ago
News Placeholder
Adverum Biotechnologies (ADVM) Receives a Buy from Oppenheimer
In a report released today, Francois Brisebois from Oppenheimer maintained a Buy rating on Adverum Biotechnologies (ADVM Research Report), with a...
TipRanks Financial Blog·1y ago
News Placeholder
Buy Rating for Adverum Biotechnologies Based on Promising Ixo-Vec Therapy and Strategic Growth Opportunities
TD Cowen analyst Joseph Thome has maintained their bullish stance on ADVM stock, giving a Buy rating on August 2. Joseph Thome has given his Buy ra...
TipRanks Financial Blog·1y ago

Latest ADVM News

View

Advertisement|Remove ads.

Advertisement|Remove ads.